2012
DOI: 10.1016/j.jhep.2012.02.029
|View full text |Cite
|
Sign up to set email alerts
|

FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
140
3
2

Year Published

2013
2013
2021
2021

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 170 publications
(152 citation statements)
references
References 28 publications
7
140
3
2
Order By: Relevance
“…However, a recent report showed that the numbers and suppressive function of FOXP3 + T cells isolated from AIH patients were similar to those of normal controls. In addition, the intrahepatic frequency of these cells was higher and correlated with the degree of inflammation in the liver of AIH patients (47). Our results support the latter observations and suggest that in Traf6ΔTEC mice, inflammation-driven production of iTregs in the liver may compensate for the reduced nTreg thymic output and drive the chronic nature of the disease.…”
Section: Methodssupporting
confidence: 85%
“…However, a recent report showed that the numbers and suppressive function of FOXP3 + T cells isolated from AIH patients were similar to those of normal controls. In addition, the intrahepatic frequency of these cells was higher and correlated with the degree of inflammation in the liver of AIH patients (47). Our results support the latter observations and suggest that in Traf6ΔTEC mice, inflammation-driven production of iTregs in the liver may compensate for the reduced nTreg thymic output and drive the chronic nature of the disease.…”
Section: Methodssupporting
confidence: 85%
“…3 Moreover, we have found that the expression levels of CD25 seemed to be associated with disease activity. 3 Thus, both disease activity and treatment status of AIH patients might have an effect on the phenotype of T cells, including CD25…”
Section: Cd39mentioning
confidence: 88%
“…However, we would like to emphasize recent reports advancing a more cautionary tone concerning in vitro efficacy and safety of these medications. 3,4 Cirrhosis patients are typically excluded from clinical trials assessing anticoagulants and clinicians are often left to extrapolate when developing treatment plans in this challenging population. While our series is small and no significant bleeding occurred, there is certainly risk when using these new agents, as the ability to monitor and rescue from bleeding is currently limited.…”
Section: Treating Thrombosis In Cirrhosis Patients With New Oral Agenmentioning
confidence: 99%
“…These T cells are normally suppressed by regulatory T cells (Treg); however, once this mechanism is disrupted, immune tolerance disturbances and the onset of autoimmune disease subsequently follow. Based on the reduction in peripheral Treg cells and TGF-β production in the setting of AIH, quantitative and qualitative defects of Treg were originally suggested to be involved in the pathogenesis of AIH, until recent evidence contradicted this hypothesis (37)(38)(39). Therefore, further investigations on this issue are needed.…”
Section: ) Acquired Immunitymentioning
confidence: 99%